Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ombitasvir/Paritaprevir/Ritonavir in Chronic HCV Patients with Renal Impairment
NCT03341988Phase 1Completed
- Sponsor
- Assiut University
- Start
- Nov 2017
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ombitasvir + paritaprevir + ritonavir in hepatitis C virus infection, sponsored by Assiut University. Primary endpoint: Sustained Viral Response at 6 months. Started Nov 2017; status: completed.
02
Drugs
ombitasvir + paritaprevir + ritonavir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NCT03341988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03341988.